IlluminaILMN
ILMN
About: Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Employees: 8,970
0
Funds holding %
of 7,296 funds
0
Analysts bullish %
of 9 analysts
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more call options, than puts
Call options by funds: $139M | Put options by funds: $116M
0.34% more ownership
Funds ownership: 97.36% [Q4 2024] → 97.7% (+0.34%) [Q1 2025]
3% less repeat investments, than reductions
Existing positions increased: 261 | Existing positions reduced: 268
16% less funds holding
Funds holding: 841 [Q4 2024] → 708 (-133) [Q1 2025]
27% less funds holding in top 10
Funds holding in top 10: 15 [Q4 2024] → 11 (-4) [Q1 2025]
40% less capital invested
Capital invested by funds: $20.6B [Q4 2024] → $12.3B (-$8.33B) [Q1 2025]
58% less first-time investments, than exits
New positions opened: 88 | Existing positions closed: 209
Research analyst outlook
9 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$77
11%
downside
Avg. target
$107
23%
upside
High target
$185
113%
upside
9 analyst ratings
4 positive
44%
4 neutral
44%
1 negative
11%
Canaccord Genuity Kyle Mikson | 14%upside $99 | Hold Maintained | 11 Jun 2025 |
Stephens & Co. Mason Carrico | 21%upside $105 | Overweight Reiterated | 20 May 2025 |
Piper Sandler David Westenberg | 113%upside $185 | Overweight Maintained | 15 May 2025 |
Morgan Stanley Tejas Savant | 15%upside $100 | Equal-Weight Maintained | 12 May 2025 |
JP Morgan Julia Qin | 2%downside $85 | Neutral Maintained | 9 May 2025 |
Financial journalist opinion
Based on 10 articles about ILMN published over the past 30 days
Neutral
PRNewsWire
4 days ago
lllumina releases 2024 Corporate Social Responsibility Report as it advances its vision to unlock the power of genomics
SAN DIEGO , June 10, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN), aligned with its commitments to advance the power of genomics, today published its annual Corporate Social Responsibility (CSR) Report. The report spotlights the ways Illumina is making precision health more accessible than ever before, and its ongoing work to empower people and communities, embed sustainability across its business, operate responsibly, and lead with integrity.
Neutral
Zacks Investment Research
2 weeks ago
Illumina Introduces a New AI algorithm PromoterAI: Stock to Gain?
ILMN unveils PromoterAI to decode noncoding genetic variants, aiming to drive breakthroughs in rare disease diagnosis.
Neutral
PRNewsWire
2 weeks ago
Illumina unveils PromoterAI, a groundbreaking algorithm to accelerate insights for rare disease diagnosis
New AI algorithm accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome at scale for the first time SAN DIEGO , May 29, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today unveiled PromoterAI, a new AI algorithm that accurately deciphers pathogenic regulatory genetic variants in the noncoding regions of the human genome. A study published today in Science illustrates how this deep learning technology discovered regulatory variants in noncoding "promoter" segments that contribute up to 6% of the genetic causes of rare diseases.
Neutral
Seeking Alpha
2 weeks ago
Illumina, Inc. (ILMN) Bernstein 41st Annual Strategic Decisions Conference (Transcript)
Illumina, Inc. (NASDAQ:ILMN ) Bernstein 41st Annual Strategic Decisions Conference Call May 28, 2025 2:30 PM ET Company Participants Jacob Thaysen - Chief Executive Officer Conference Call Participants Eve Burstein - Bernstein Eve Burstein All right. Thank you so much, everyone, for joining.
Positive
CNBC Television
2 weeks ago
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Positive
Zacks Investment Research
2 weeks ago
Illumina's TSO Comprehensive Earns Japan's Approval: Stock to Gain?
Japan approves ILMN's TSO Comprehensive, marking a key step forward in global precision oncology adoption and clinical use.
Neutral
PRNewsWire
2 weeks ago
Illumina expands clinical oncology portfolio unlocking new standard of care and access to precision therapies
Following FDA approval last year, Illumina's TSO Comprehensive test gains broad payer reimbursement, expanding access to comprehensive genomic profiling to match patients with targeted therapies Illumina's IVD portfolio will also expand to offer Pillar oncoReveal® CDx, the newest panel to deliver critical companion diagnostic testing using the Illumina MiSeq™ Dx System SAN DIEGO , May 28, 2025 /PRNewswire/ -- Illumina Inc. (NASDAQ: ILMN) today announced an expanded clinical oncology portfolio, unlocking the next new solutions to advance precision oncology and improve the standard of care. The company's broad range of clinical offerings will accelerate access to precision oncology for more patients with cancer.
Positive
Zacks Investment Research
3 weeks ago
Illumina Stock to Gain From the Launch of New DRAGEN v4.4 Software
ILMN's latest software features easy-to-use oncology apps, enhanced multiomics pipelines and AWS F2 support, enabling faster turnaround times.
Neutral
Business Wire
3 weeks ago
Signios Bio and Illumina Announce Grant to Maximize Discovery Power with Industry's Largest NGS-Based Proteomics Panel
FOSTER CITY, Calif.--(BUSINESS WIRE)--Signios Biosciences (“Signios Bio”), a science-first biotechnology company leading in multiomics and AI-powered bioinformatics, in collaboration with Illumina, announced today an Illumina-sponsored grant for Early Access to Illumina Protein Prep 9.5K™. Powered by SOMAmer® technology, this next-generation sequencing (NGS)-based platform enables comprehensive proteomic profiling of plasma and serum. Illumina Protein Prep 9.5K™ utilizes slow off-rate modified.
Positive
Benzinga
4 weeks ago
Icahn Ramps Up Bets On Genes And Jets: Illumina Stake Jumps 450%, JetBlue Holding Grow 90%
Carl Icahn is making bold moves from the lab to the tarmac.
Charts implemented using Lightweight Charts™